Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- CINPHA.ST
- Price
- 17.40
- Stock movement down
- -0.32 (-1.93%)
- Company name
- Cinclus Pharma
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 758.57M
- Ent value
- -
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -37.25%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-10-30
DIVIDENDS
CINPHA.ST does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 16.16 |
| Daily high | 16.64 |
| Daily low | 15.92 |
| Daily Volume | 15K |
| All-time high | 35.00 |
| 1y analyst estimate | 55.00 |
| Beta | - |
| EPS (TTM) | - |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CINPHA.ST | S&P500 | |
| Current price drop from All-time high | -50.29% | -4.13% |
| Highest price drop | -73.06% | -19.00% |
| Date of highest drop | 7 May 2025 | 8 Apr 2025 |
| Avg drop from high | -51.39% | -2.73% |
| Avg time to new high | - | 6 days |
| Max time to new high | 265 days | 89 days |
COMPANY DETAILS
Marketcap
758.57M
Marketcap category
Small-cap
Description
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H. pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
Employees
20
Website
Investor relations
-
SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found